Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

ConferenceobexelimabPositive

AI Analysis

Summary

Zenas BioPharma announced upcoming presentations of Phase 3 INDIGO open-label extension data for obexelimab in IgG4-Related Disease at the IgG4ward! 6th International Symposium and ACR Convergence 2026, including longer-term flare protection and safety data.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Phase 3 INDIGO open-label extension data on longer-term flare protection and safety to be presented

Importance:4/10

Sentiment:

0.30

obexelimabIgG4-RDPhase 3conference presentationopen-label extensionflare protection

Related Companies

$ISCO

Read the original article

Published by GlobeNewswire Clinical Studies on September 22, 2026 11:05 AM

Read Original